Compositions and method for multimodal imaging

ABSTRACT

Provided are signal modifying compositions for medical imaging comprising a carrier and two or more signal modifying agents specific for two or more imaging modalities. The compositions are characterized by retention efficiency, with respect to the signal modifying agents, which enables prolonged contrast imaging without significant depletion of the signal modifying agents from the carrier. The carriers of the present invention are lipid based or polymer based, the physico-chemical properties of which can be modified to entrap or chelate different signal modifying agents and mixtures thereof and to target specific organs or tumors or tissues within a mammal.

CROSS REFERENCE TO RELATED APPLICATION

This application is a 35 USC §371 National Phase Entry Application fromPCT/CA2006/000207, filed Feb. 10, 2006, and designating the UnitedStates, and claims the benefit of U.S. Provisional 60/651,638, filedFeb. 11, 2005.

FIELD OF THE INVENTION

This invention relates to the field of medical imaging and morespecifically to the use of signal modifying agents in medical imaging.

BACKGROUND OF THE INVENTION

In recent years significant effort has been devoted to the developmentof multimodality imaging. Since each medical imaging modality has uniquestrengths and limitations, it is often through the compound use ofmultiple modalities that the complete assessment of a patient isachieved. Interest in the area of multimodality imaging has also beenprompted by the realization that such techniques offer much moresophisticated characterization of the morphology and physiology oftissues and organs, and that confidence gained in the accuratecorrespondence or registration of different modalities greatly enhancestheir value (Barillot C, Lemoine D, Le Briquer L, et al. Eur J Radiol1993; 17:22-27.). Consequently, this improved value of imaging willultimately allow for advances in diagnosis and evaluation of disease,image-guided therapeutic interventions, and assessment of treatmentoutcomes. The recent integration of computed tomography (CT) andpositron-emission tomography (PET) systems is a good example of theadvantages of the multimodal approach (Townsend D W. Mol Imaging Biol2004; 6:275-290; Townsend D W, Carney J P, Yap J T, et al. J Nucl Med2004; 45 Suppl 1:4S-14S; Townsend D W, Beyer T. Br J Radiol 2002; 75Spec No:S24-30). The CT-PET combination has revolutionized theutilization of PET and served to increase the specificity of PET-basedassessment. In the context of radiation therapy, there is a need tomerge CT and magnetic resonance (MR) imaging with CT employed for 3Dvolumetric dose calculation (Rosenman J G, Miller E P, Tracton G, et al.Int J Radiat Oncol Biol Phys 1998; 40:197-205.) and MR for accuratedelineation of the target and normal structures as it providesexceptional soft tissue definition. For example, accurate delineationand targeting of the prostate gland in radiation therapy of prostatecancer necessitates parallel use of CT and MR imaging (Rasch C, BarillotI, Remeijer P, et al. Int J Radiat Oncol Biol Phys 1999; 43:57-66.).Furthermore, CT technology in the form of conventional and cone-beamsystems is employed on a daily basis to guide the delivery of radiationtherapy on treatment machines (Uematsu M, Sonderegger M, Shioda A, etal. Radiother Oncol 1999; 50: 337-339; Jaffray D A, Siewerdsen J H, WongJ W, et al. Int J Radiat Oncol Biol Phys 2002; 53:1337-1349.).

Clinical imaging in all modalities requires an adequate level ofdifferential contrast relative to noise be achieved in order to identifythe structures or phenomena under observation. Although imaging on CTand MR can be performed without the administration of signal modifyingagents there are numerous instances in both disease diagnosis andtreatment, in which procedures benefit from the improved contrast anddynamics that are added by the use of these agents (Krause W. Adv DrugDeliv Rev 1999; 37: 159-173; Saeed M, Wendland M F, Higgins C B. J MagnReson Imaging 2000; 12:890-898).

To date, although a multitude of signal modifying agents arecommercially available for single modality imaging, few attempts havebeen made to develop signal modifying agents that can be used acrossmultiple imaging modalities (McDonald M A, Watkin B S, Watkin K L. SmallInvest Radiol 2003; 38:305-310; Bloem J L, Wondergem J. Radiology 1989;171:578-579; Gierda D S, Bae K T. Radiology 1999; 210: 829-834; Quinn AD, O'Hare N J, Wallis F J, et al. J Comput Assist Tomogr 1994; 18:634-636; Pena C S, Kaufman J A, Geller S C, et al. J Comput AssistTomogr 1999; 23:23-24.). The lack of development in this area is likelydue to challenges presented by the fact that the distinct imagingmodalities have different sensitivities for different signal modifyingagents (Krause W. Adv Drug Deliv Rev 1999; 37: 159-173.). A simpleapproach for realizing a multimodal signal modifying agent for CT and MRhas been to exploit commercially available extracellulargadolinium-based signal modifying agents for enhancement in both ofthese modalities. In this case, the properties of gadolinium that allowfor use in both CT and MR include its relatively high atomic number andparamagnetic characteristics (McDonald M A, Watkin B S, Watkin K L.Small Invest Radiol 2003; 38: 305-310; Bloem J L, Wondergem J. Radiology1989; 171:578-579; Gierda D S, Bae K T. Radiology 1999; 210: 829-834;Quinn A D, O'Hare N J, Wallis F J, et al. J Comput Assist Tomogr 1994;18:634-636; Pena C S, Kaufman J A, Geller S C, et al. J Comput AssistTomogr 1999; 23:23-24.). However, due to their low molecular weight,these agents only remain in the vascular system for a short period oftime, exhibit rapid dynamic distribution changes in different organs andare excreted quickly. The use of these agents for cross-modality imagingwould therefore require both multiple administrations and fast imagingsequences. Also, the low gadolinium payload per molecule, relative toconventional iodinated signal modifying agents, would necessitate theadministration of higher doses for adequate CT enhancement which mayhave implications in terms of both cost and toxicity (McDonald M A,Watkin B S, Watkin K L. Small Invest Radiol 2003; 38:305-310; Bloem J L,Wondergem J. Radiology 1989; 171:578-579; Gierda D S, Bae K T. Radiology1999; 210:829-834; Quinn A D, O'Hare N J, Wallis F J, et al. J ComputAssist Tomogr 1994; 18:634-636; Pena C S, Kaufman J A, Geller S C, etal. J Comput Assist Tomogr 1999; 23:23-24.). Furthermore, the short invivo residence time of these agents would impose limitations on the sizeof the anatomic region that could be imaged optimally and would excludethem from being used in image-guidance applications due to theirinability to provide prolonged contrast enhancement for the entirecourse of treatment (Saeed M, Wendland M F, Higgins C B. J Magn ResonImaging 2000; 12:890-898).

A viable way to effectively deliver the required amount of contrast ineach imaging modality and to prolong the presence of the agents in vivois to employ carriers such as liposomes. Specifically, liposome-basedsystems have been evaluated for either encapsulating (Kao C Y, Hoffman EA, Beck K C, et al. Acad Radiol 2003; 10:475-483; Leike J U, Sachse A,Rupp K. Invest Radiol 2001; 36:303-308; Leander P, Hoglund P, Borseth A,et al. Eur Radiol 2001; 11:698-704; Schmiedl U P, Krause W, Leike J, etal. Acad Radiol 1999; 6:164-169; Spinazzi A, Ceriati S, Pianezzola P, etal. Invest Radiol 2000; 35:1-7; Petersein J, Franke B, Fouillet X, et alInvest Radiol 1999; 34:401-409; Leander P, Hoglund P, Kloster Y, et al.Acad Radiol 1998; 5 Suppl 1:S6-8; discussion S28-30; Krause W, Leike J,Schuhmann-Giampieri G, et al. Acad Radiol 1996; 3 Suppl 2:S235-237; DickA, Adam G, Tacke J, et al. Invest Radiol 1996; 31:194-203; Revel D,Corot C, Carrillon Y, et al. Invest Radiol 1990; 25 Suppl 1:S95-97; MusuC, Felder E, Lamy B, et al. Invest Radiol 1988; 23 Suppl 1:S126-129;Zalutsky M R, Noska M A, Seltzer S E. Invest Radiol 1987; 22:141-147;Seltzer S E, Shulkin P M, Adams D F, et al. AJR Am J Roentgenol 1984;143:575-579; Jendrasiak G L, Frey G D, Heim R C, Jr. Invest Radiol 1985;20:995-1002; Torchilin V P. Curr Pharm Biotechnol 2000; 1:183-215;Schneider T, Sachse A, Robling G, Brandl M. Int J Pharm 1995; 117:1-12;Pauser S, Reszka R, Wagner S, et al. Anticancer Drug Des 1997;12:125-135.) or chelating (Weissig W, Babich J, Torchilin W. ColloidsSurf B Biointerfaces 2000; 18:293-299; Misselwitz B, Sachse A. ActaRadiol Suppl 1997; 412:51-55; Unger E, Needleman P, Cullis P, et al.Invest Radiol 1988; 23:928-932; Kabalka G, Buonocore E, Hubner K, et al.Radiology 1987; 163:255-258; Grant C W, Karlik S, Florio E. Magn ResonMed 1989; 11:236-243) single CT or MR signal modifying agents. Most ofthese liposome-based signal modifying agents have been explored forblood pool imaging due to the long in vivo circulation lifetimes thatmay be achieved for these carriers. Yet, liposomes have also beenidentified as suitable carriers for the delivery of agents to thelymphatic system since they have been shown to avoid aggregation at thesite of injection and localize in lymph nodes (Nishioka Y, Yoshino H.Adv Drug Deliv Rev. 2001; 47:55-64; Moghimi S M, Rajabi-Siahboomi A R.Prog Biphys Molec Biol. 1996; 65:221-249; Oussoren C, Storm G. Adv DrugDeliv Rev 2001; 50:143-156). The potential use of liposome-based signalmodifying agents for lymphatic imaging is worth noting as it iswell-known that the lymph nodes are the primary site for the metastasesof many cancers (Swartz M A. Adv Drug Deliv Rev. 2001; 50:3-20; Swartz MA, Skobe M. Microsc Res Tech 2001; 55:92-99.). Until recently, therewere no available non-invasive methods for distinguishing between lymphnodes enlarged due to the presence of metastatic cancer cells and nodesenlarged due to inflammation, or for identifying cancerous nodes ofnormal size. With the advent of Combidex® (Advanced Magnetics, Inc.USA), lymph nodes can now be enhanced in MR, and metastatic nodes can bedifferentiated from normal or inflamed nodes based on morphology andchanges in signal intensity between scans performed before and aftersignal modifying agent injection (Xiang Y, Wang J, Hussain S M, KrestinG P. Eur Radiol. 2001; 11:2319-2331). However no delivery system hasbeen developed for prolonged co-localization in vivo of two or moresignal modifying agent for multiple medical imaging.

SUMMARY OF THE INVENTION

In a broad aspect of the invention there is provided signal modifyingcompositions for medical imaging comprising a carrier and signalmodifying agents specific for two or more imaging modalities. In apreferred embodiment the compositions are characterized by retentionefficiency, with respect of the signal modifying agents, that enablesprolonged contrast imaging without depletion of the signal modifyingagent from the carrier. The carriers of the present invention are lipidbased or polymer based the physico-chemical properties of which can bemodified to entrap or chelate different signal modifying agents andmixtures thereof and to target specific organs or tumors within amammal.

The co-localization of imaging modalities specific signal modifyingagents in a carrier advantageously enables the registration of imagesobtained from different imaging modalities. The registration can beexploited to refine diagnosis, design of therapeutic regimen, follow theprogress of therapy such as radiation therapy and optimize contrastenhancement.

Thus, in one aspect, there is provided an image signal modifiercomposition for imaging of a biological tissue, the compositioncomprising: two or more signal modifying agents, each of the agent beingspecific for at least one imaging modality; and a carrier comprising thetwo or more signal modifying agents and wherein the carrier is capableof retaining a sufficient amount of the agents for a time sufficient toacquire imaging data using the composition.

The signal modifying agents are specific for imaging modalities selectedfrom but not limited to magnetic resonance imaging (MRI), X-ray,ultrasound (US), positron emission tomography (PET), computed tomography(CT), autoradiography, single-photon emission computed tomography(SPECT), fluoroscopy, optical imaging, fluorescence imaging andbioluminescence imaging.

In a further aspect, the carrier is a lipid-based carrier such as aliposome or a micelle.

In an embodiment of the invention the composition can be targeted to adesired location within a subject or within a tissue. This can beachieved through control of the carrier physico-chemical properties orby inserting one or more recognition molecules such as antibodies,receptors/ligands, carbohydrates, proteins and peptide fragments.

In another embodiment the may comprise a therapeutic agent such asanticancer, antimicrobial, antifungal and antiviral agents.

In yet another aspect of the invention the there is also provided amethod for imaging one or more region of interest in a mammal the methodcomprising: administering to the mammal a signal modifier compositionwaiting for a time sufficient for the composition to reach the region ofinterest; and obtaining an image of the one or more region of interest.

There is also provided a method for registering images obtained from twoor more imaging modalities the method comprising: administering to amammal a signal modifier composition, each agent being specific for atleast one of the at least two or more imaging modalities; obtaining animage of one or more region of interest in the mammal using each of theat least two or more imaging modalities; and comparing the imagesobtained in b) to derive complementary information from the one or moreregion of interest.

In the present description by signal modifier or signal modifying it ismeant that the signal obtained with a particular imaging modality ismodified by an agent. Typically the agent is a signal enhancing agent(contrast agent) but the agent may also provide for signal attenuationor any other form of signal modification so as to provide a desiredeffect on the image.

By biological tissue or tissue it is meant any part of an animal, suchas a mammal, including but not limited to organs, vessels, blood, breasttissue, muscular tissue, bones and the like.

By retaining or retention efficiency it is meant the capacity of acarrier to prevent leakage of a signal modifier agent out of thecarrier.

By targeting it is meant the preferential accumulation of thecompositions of the present invention in a given organ or anatomicalstructure or tissue, including cell populations. By active targeting itis meant that a target binding molecule, specific for a molecule in thetarget, is incorporated in (or associated with) the composition.Examples comprise antibodies and receptor/ligand pairs. Passivetargeting refers to preferential distribution of the composition due toits physico-chemical properties.

BRIEF DESCRIPTION OF THE DRAWINGS

Further features and advantages of the present invention will becomeapparent from the following detailed description, taken in combinationwith the appended drawings, in which:

FIG. 1 is a schematic representation of the liposome-based signalmodifying agent system;

FIG. 2 is a transmission electron micrograph of the negatively staineddual-agent containing liposomes at (a) 40000 magnification and (b) 80000magnification;

FIG. 3 is an in vitro release profile for lohexol and Gadoteridol fromDPPC/cholesterol/DSPE-PEG (55/40/5 mol %) liposomes dialyzed under sinkconditions (250-fold volume excess) against HBS (a) at 4° C. (n=3) and(b) at 37° C. (n=4);

FIG. 4 is a plot of the size of the dual agent-containing liposomesduring dialysis under sink conditions (250-fold volume excess) againstHBS at 37° C. (n=3);

FIG. 5 is an image showing in vitro imaging efficacy of theliposome-based signal modifying agent system (a) in CT (2.5 mm slicethickness, 120 kV, 300 mA and 15.2 cm FOV) and (b) in MRI (450 ms TR, 9ms TE, 3 mm slice thickness, 19.9 cm FOV and 256×192 image carrier)

[iodine] (mg/mL) [gadolinium] (mg/mL) A 16.98 3.55 B 8.49 1.77 C 1.700.35 D 0.17 0.04 E 0.07 0.02

FIG. 6 (a) CT (2.5 mm slice thickness, 120 kV, 300 mA and 15.2 cm FOV)attenuation in HU as a function of signal modifying agent concentrationin mmol/L; although gadolinium has CT attenuation properties, iodineprovides more effective CT enhancement. (b) Differential signalintensity (with respect to water) in MRI (400 ms TR, 9 ms TE, 3 mm slicethickness, 19.9 cm FOV and 256×192 image carrier) as a function ofincreasing gadolinium and iodine concentrations; symbols representliposome encapsulated agents (▪), free lohexol and Gadoteridol (▴), freeGadoteridol (●) and free lohexol (▾);

FIG. 7 (a) 1/T1 relaxation rate and (b) 1/T2 relaxation rate as afunction of gadolinium (Gd) and iodine (I) concentration obtained at 20°C. with a 1.5 T, 20-cm-bore superconducting magnet controlled by an SMISspectroscopy console; Encapsulation of Gadoteridol greatly reduces boththe r₁ and r₂ of the gadolinium atoms;

r₁ r₂ (s⁻¹mmol⁻¹L) (s⁻¹mmol⁻¹L) (▪) Free Gadoteridol 5.14 ± 0.06 6.21 ±0.08 (●) Free Gadoteridol and Iohexol 6.38 ± 0.16 7.83 ± 0.20 (1:29 moleratio of Gd to I) (▴) Free Iohexol 0.00 ± 0.00 0.01 ± 0.01 (x-axis = [I]in mmol/L) (▾) Liposome encapsulated agents 1.23 ± 0.02 1.46 ± 0.02

FIG. 8 is a liver cross-section images from a rabbit, before and afterinjection of signal modifying agent, in CT and MR;

FIG. 9 is a confocal microscopy image of a liposome formulationcontaining DPPC/Cholesterol/DSPEPEG/DPPE-NDB 1 (54.5/40/510.5 moleratios) encapsulating iohexol and gadoteridol;1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(7-nitro-2-1,3-benzoxadiaxol-4-yl),the excitation wavelength is 460 nm and the emission wavelength is 534nm; this liposome formulation is suitable for CT, MR and opticalimaging;

FIG. 10 is a graphic of a relative signal enhancement of blood (aorta),liver (parenchyma) and kidney (medulla and cortex) up to 200 minutesfollowing intravenous administration of the liposome-based signalmodifying agent in (a) CT and (b) MR;

FIG. 11 is (a) CT and MR liver cross section scans of a 2.1 kg white NewZealand rabbit obtained before (0 min.) and after (10, 30, 90 and 200minutes) signal modifying agent injection. Note the visual contrastenhancement obtained in the aorta, the hepatic vessels, and the liverparenchyma up to 3 hours and 20 minutes in both imaging modalities. (b)CT and MR cross section scans of the left kidney obtained before (0min.) and after (10, 60, 120 and 200 minutes) signal modifying agentinjection. Note the visual contrast enhancement obtained in the kidney.The same window level was used for pre- and post-injection images;

FIG. 12 are 3D maximum intensity projection images (anterior view) ofthe rabbit in CT (120 kV, 200 mA) and MR (3D FSPGR, TR/TE=9.8/4.3)before the injection of the contrast agent modified liposomes (0minutes) and 48 hours and 168 hours post-injection (300 mg/kg of iodineand 16 mg/kg of gadolinium encapsulated in liposomes), the parallelvisual enhancement seen in both CT and MR obtained in the major bloodvessels, liver, spleen and intestines represents the liposomedistribution over a 7-day period, the spine and part of the ribs of therabbit have been masked in the CT image set for better soft tissuevisualization;

FIG. 13 is a graphic of the percentage of the total injected CT(iohexol, detected with HPLC at 245 nm wavelength) or MR agent(gadoteridol, detected with ICP-AES) remaining in mouse plasma (femaleBalb-C, 18-23 g, one mouse per time point) and rabbit plasma (female NewZealand White, 2 kg, same rabbit used for all time points) at specifictime points following administration, the ratio of iodine to gadoliniumis 13.9±3.0 in mice and 11.9±0.5 in the rabbit at all time points;

FIG. 14 is a liposome distribution estimated from the percentage of theinjected gadolinium encapsulated in liposomes per gram of tissue(kidney, liver, spleen, heart and lung) over a 8-day period in femaleBalb-C mice; and

FIG. 15 are relative signal differences measured in the rabbit aortausing CT and MR correlate linearly (R²=0.9) with the iodine andgadoteridol concentrations detected in the rabbit plasma using HPLC andICP-AES assays, respectively, the relative HU (ΔHU_(rel)) was calculatedas a function of the HU value found at the same anatomic location priorto the injection of the liposome sample (ΔHU₀) as described in equation(1), similarly, the relative MR signal intensity (ΔSi_(rel)) wascalculated as a function of the pre-injection signal intensity value(ΔSI₀) as described in equation (2).

$\begin{matrix}{{\Delta\;{HU}_{rel}} = {{\frac{\left( {{\Delta\;{HU}_{rel}} - {\Delta\;{HU}_{0}}} \right)}{\Delta\;{HU}_{0}}\mspace{14mu}\Delta\;{SI}_{rel}} = \frac{\left( {{\Delta\;{SI}_{rel}} - {\Delta\;{SI}_{0}}} \right)}{\Delta\;{SI}_{0}}}} & (1)\end{matrix}$

DETAILED DESCRIPTION OF THE INVENTION

A novel approach is provided, in which image signal modifiercompositions are designed to provide long-lasting image signals foraccurate spatial registration over the course of therapy or diagnosisand between imaging-modalities used in the design and guidance of thetherapy. Such a composition provides a unique platform for accuratedesign, image-guided delivery, and assessment of therapy.

Thus, there is provided compositions and methods for signal modificationsuch as contrast enhancement in imaging modalities. In one aspect thereis provided multimodal signal modifier compositions that comprise atleast two signal modifying agents and a carrier, each signal modifyingagent being specific for at least one imaging modality. The combinationof the signal modifying agents enables the co-localization, withinspecific anatomical structures as part of biological tissues (organs,tumors and the like) of mammals (including humans), of the signalmodifying agents which, in turn, allows acquisition of the imagesobtained by two (or more) imaging modalities and also allows forregistration of the images. Such compositions may be used for imagingvarious organs and tissues as well as any tubule and vessel system inthe body (i.e. blood vessels, hepatic vessels, renal vessels, and thelymphatics).

The multimodal signal modifier compositions of the present invention maybe used with imaging modalities that are based on magnetic resonance,ultrasound, X-ray, optical, positron-emission, single-photon emission,radioactivity and the like provided that the signal modifying agentspossess the required signal modifying properties as would be known to aperson skilled in the art. For example in the case of magnetic resonanceimaging (MRI) the signal modifying agent should possess magneticproperties (high relaxivity) capable of modifying the relaxation time ofbulk water molecules. As another example, signal modifying agents forX-ray imaging should exhibit bulk attenuation characteristics. Signalmodifying agents can possess properties that render them suitable forsignal modification of more than one imaging modality. A carrier maycomprise any combination of signal modifying agent. Non-limitingexamples include: signal modifying agents for MRI/X-ray, MRI/optical,MRI/X-ray/optical, optical/PET, MRI/CT/optical, etc.

Signal modifying agents specific for each imaging modalities (CT, MR′radionuclide, optical) are well known in the art. Non-limiting examplesof signal modifying agents include gadolinium, manganese and iron basedagents (MRI), iodine based agent (CT), alpha, beta and positron emittingradiotracers (autoradiography, PET and SPECT), fluorophores (optical),and perfluorocarbons.

The multimodal signal modifier compositions of the present inventioncomprise a carrier having physico-chemical properties compatible withthe retention of the signal modifying agents. Retention of the signalmodifying agent molecules is desirable to prevent dispersion of theagent within the body and to prevent the depletion of the signalmodifying agents from the carrier, which would reduce the signalintensity. Thus, effective retention results in prolonged in vivocontrast enhancement thereby avoiding the need for multipleadministration over the course of image acquisition and allowingregistration of images obtained over a period of time. In a preferredembodiment the carrier can retain between about 10 and 100% of thesignal modifying agent over the course of imaging. In a more preferredembodiment this retention is of the order of about 80 to 100% and in aneven more preferred embodiment the retention is above 90%. Thus thecarrier should be sufficiently stable with respect to agents' retentionso as to allow sufficient time for the composition to reach a region ofinterest an enable acquisition of imaging data. Furthermore the carriershould also remain in the tissue of interest for a time sufficient toallow acquisition of imaging data over a desired period of time. Thisperiod of time may depend on the information that is required, thenature of therapeutic regimens being applied, the progression of adisease and the like. The period of time may extend from a few minutesto several days.

In one embodiment, the carrier is used to entrap (encapsulate) thesignal modifying agents and in a preferred embodiment the carrierconsists of a lipid based carrier such as lipid micelles, unilamellar(see FIG. 1) and multilamellar vesicles such as liposomes.

Lipid micelles have small diameters: 8 nm-50 nm and are made of a singlelipid layer and are therefore suitable for encapsulating hydrophobicsignal modifying agents, such as Perfluorooctyl bromide (perflubron).

The composition of the carrier may be adjusted as required in order tooptimize the loading capacity, release kinetic profiles for each agent,and the stability of the overall system. For example, for a lipid-basedcarrier such as liposome, it is well known that the membrane fluiditymay affect the permeability of certain compounds. The molecularcharacteristics of the membrane that are known to affect fluidityinclude, but are not limited to, lipid saturation, fatty acid chainlength, charge of the polar head of the lipids, cholesterol content andthe like. It will be appreciated that encapsulation of the signalmodifying agents should not substantially affect their signal modifying(for example contrast enhancing) properties. In this respect, thecomposition of the carrier preferably minimizes the leakage of theencapsulated agents and optimizes the contrast enhancement abilities ofthe encapsulated agents. For example, bulk water accessibility to signalmodifying agents should be considered when designing a carriercomposition for MRI. It will also be appreciated that the signalmodifying agents may be chosen to be compatible with a given carriercomposition. For example, while a signal modifying agent may be prone toleak out of a liposome having a given lipid composition, a differentsignal modifying agent may be less so for the same lipid composition.

In a preferred embodiment the lipid composition of the lipid basedcarrier comprises a neutral lipid, cholesterol and polyethylene glycol(PEG₂₀₀₀)-phosphatidylethanolamine (PE).

A second approach to couple the signal modifying agent(s) to the carrierinvolves chelation or covalent linking of at least one of the signalmodifying agents to the outer surface of the carrier (such as aliposome). This approach can, for example, increase the access to bulkwater thereby enhancing the efficiency of MR signal modifying agents.This strategy also maximizes the entire internal aqueous volume of thecarrier as cargo space for the other or several other signal modifyingagents. For example, radionuclides can be chelated on derivatizedlipids. Hydrophilic agents can be chelated (see below) onto their outersurface along with Poly-ethylene glycol (PEG) groups. Chelators maycomprise EDTA, DTPA, TETA, HYNIC and other structurally relatedanalogues. It will be appreciated that coupling of signal modifyingagents may comprise high affinity linker molecules such asavidin-biotin. The signal modifying agent may also be covalently linkedto the carrier. For example fluorophore can be thus linked to lipidmolecules that can in turn be incorporated in a lipid carrier.

The encapsulation (or chelation) of small molecular weight signalmodifying agents into a macromolecule carrier (i.e. liposome)significantly reduces their in vivo volume distribution, prolongs theirin vivo circulation time and increases their ability to accumulate inspecific locations within the body such as in tumors. It will beappreciated that accumulation may take place through passive or activetargeting mechanisms. With respect to active targeting mechanisms,techniques such as antibody coating or attachment of specific cellularreceptors/ligands (such as Epidermal Growth Factor, EGF and itsreceptor, EGFR) onto the surface of the carrier or in association withpolymeric matrices may be used as would be known to those skilled in theart. Non-limiting examples also include small molecules (Saul J M,Annapragada A, Natarajan J V, et al. J Control Release 2003; 92:49-67;Lee R J, Low P S. Biochim Biophys Acta 1995; 1233:134-144; Lee R J, LowP S. J Biol Chem 1994; 269:3198-3204.), sugar (carbohydrates) molecules(Spanjer H H, Scherphof G L. Biochim Biophys Acta 1983; 734:40-47;Spanjer H H, Morselt H, Scherphof G L. Biochim Biophys Acta 1984;774:49-55; Banerjee G, Nandi G, Mahato S B, et al. J AntimicrobChemother 1996; 38:145-150; Luciani A, Olivier J C, Clement O, et al.Radiology 2004; 231:135-142.), serum proteins (Afzelius P, Demant E J,Hansen G H, et al. Biochim Biophys Acta 1989; 979:231-238; Brown P M,Silvius J R. Biochim Biophys Acta 1990; 1023:341-351; Lundberg B, HongK, Papahadjopoulos D. Biochim Biophys Acta 1993; 1149:305-312.) andantibodies (Heath T D, Montgomery J A, Piper J R, et al. Proc Natl AcadSci USA 1983; 80:1377-1381; Debs R J, Heath T D, Papahadjopoulos D.Biochim Biophys Acta 1987; 901:183-190; Matthay K K, Abai A M, Cobb S,et al. Cancer Res 1989; 49:4879-4886; Maruyama K, Holmberg E, Kennel SJ, et al. J Pharm Sci 1990; 79:978-984; Allen T M, Ahmad I, Lopes deMenezes D E, et al. Biochem Soc Trans 1995; 23:1073-1079) or antibodyfragments (Kirpotin D, Park J W, Hong K, et al. Biochemistry 1997;36:66-75; Park J W, Hong K, Carter P, et al. Proc Natl Acad Sci USA1995; 92:1327-1331.). Consequently, nonspecific toxicity can be greatlyreduced (i.e. renal-toxicity often associated with iodine-based signalmodifying agents) and specific imaging efficacy increased.

It will be appreciated that active targeting can be tested for exampleby injecting a signal modifier composition comprising a target bindingmolecule for which the target is known and measuring the amount of thecomposition reaching the target. The target may be an extrinsic target,that is to say, the target can be incorporated in an animal at apredetermined location such as a tumor expressing a particular receptorfor which the ligand is known and introduced in the composition.

The in vivo behavior of carrier such as distribution and clearancekinetics is highly dependent on the their size, composition, surfacecharacteristics and route of administration. The size distribution ofthe carrier used in the present invention is between 30 and 1000 nm,preferably between 30 and 500 nm and most preferably between 50 and 150nm.

Preferably the composition of the present invention will remain incirculation or in an organ for an extended period of time. Preferablythe composition will remain for several hours and more preferably forseveral days.

It will be appreciated that the signal modifying agents may beseparately encapsulated in or associated with carriers of the samesizes, membrane compositions and surface characteristics, conferringsimilar pharmacokinetic properties enabling the co-localization withintissues. However, the carriers may also differ in their properties andtheir pharmacokinetics properties may therefore be different. Insofar asthe differences in the pharmacokinetics are known or measured, they maybe exploited for differential localization within regions of interestsin the body.

I will be appreciated that the carriers of the invention may comprisepolymer-based material.

The contrast enhancing compositions of the present invention may alsocomprise therapeutic agents for delivery in organs/tissues/cellstargeted by the carriers. The combination of the signal modifying agentsand therapeutic agents advantageously allows the monitoring of thein-vivo distribution of therapeutic agent at least at the stage of agentdelivery and the biological effects of the therapeutic agent (such astumor shrinkage, etc.). Examples of therapeutic agents includeanticancer drugs such as anthracyclines (i.e. doxorubicin,daunorubicin), vinca alkaloids (i.e. vincristine, navelbine) and otherdrugs such as 5-FU, ara-C, camptothecin analogues (i.e. lurtotecan,topotecan), platinum-based compounds (i.e. cisplatin, carboplatin),anti-fungal agents such as amphotericin B, anti-bacterial agents such asantibiotics (minocycline, doxycycline and the like), anti-viral agentsand other therapeutic agents as would be know to those skilled in theart.

In another aspect of the invention, there is provided a method forimaging biological tissue using the image signal modifier composition ofthe invention. The image signal modifier composition is administered toa subject and one or more images can be obtained with one or moreimaging modality for which the composition provides signal modificationsuch as contrast enhancement. It will be appreciated that a timesufficient to allow distribution of the signal modifier compositionwithin the subject may be allowed prior to acquisition of the image.

The kinetics of distribution of the composition may depend on severalfactors such as the nature of the composition itself, the mode ofinjection and the like. Determination of the kinetics can be achieved,for example, by acquiring images at different times after administrationof the composition.

The properties of the signal modifying agents can also influence theduration of the signal modification. Thus it will be appreciated thatthe stability of the signal modifying agent may influence the quality ofthe image as well as the available window of time to acquire imagingdata. The half-life of radionuclides and lifetime of fluorophores areexamples of stability characteristics that should be taken inconsideration. It will be further appreciated that the optimalconcentration of the signal modifying agents within the carrier dependson the type of imaging being performed, the region of interest beingimaged, the duration of the imaging protocol, the stability of theagent, the characteristics of the agents such as specific activity,quantum efficiency and the like, and any other factor as would be knownto the person skilled in the art.

Image acquisition using the signal modifier composition of the inventionmay be used for the detection of abnormalities within biologicaltissues. By abnormalities it is meant anatomical structures not normallypresent in a tissue such a tumors for example.

In another aspect of the invention there is provided a method for theregistration of images obtained by two or more imaging modalities usingthe composition of the present invention. A multimodal signal modifiercomposition advantageously co-localize the signal modifying agentsthereby enabling the correlation of images obtained using two or moreimaging modalities. Medical images can be divided in two types.Structural (anatomical) images and functional images. Functional andmolecular imaging using single photon emission computed tomography(SPECT), positron emission tomography (PET) and optical imaging isextremely valuable in the diagnosis of various disorders. The method forthe registration of images according to the present invention allows thecorrelation between structural (anatomical), functional and molecularimages or a combination or a combination thereof thereby providingcomplementary information of a region of interest.

Furthermore, the long in vivo residence time of the compositions of thepresent invention allows for multiple scans to be obtained from one ormore imaging modalities following a single injection. This in turnenables the direct correlation of the signals obtained in distinctimaging modalities and allow for correct correspondence betweendifferent regions in the image. Thus multimodal signal modifyingcompositions may also assist in the development of novel imageregistration techniques, such as biomechanical based registration, whichcan take advantage of the clear definition of organ boundaries andsubstructures enhanced in each modality. In addition to improving theperformance of image registration techniques, this signal modifyingagent may also enhance the ability to identify naturally occurringfiducial points (i.e. vessel bifurcations) used to verify the accuracyof registration techniques.

Multimodal image registration and fusion are valuable tools for bothdiagnosis and treatment planning because the combination of informationfrom multiple sources can be applied to enhance conspicuity of relevantdata with respect to irrelevant information. Thus, image acquisition andregistration can contribute to the design, implementation and assessmentof therapeutic regimens. For example, knowledge acquired from thespatio-temporal distribution of a therapeutic compound included in thecarrier can be exploited to determine appropriate doses, frequency ofadministration, mode of administration and the like. In particular thecomposition and method of the invention can be useful to establishtherapeutic regimens for, but not limited to, cancer treatment. Forexample, combination of MRI and CT images may advantageously be used forestablishing radiation therapy protocols. The progress of the therapymay also be followed by acquiring images using more than one imagingmodality over a given time period during and after the therapy.

The composition of the present invention can also be used as a fiducialmarker. A fiducial marker is defined as a point or structure ofreference (static or not). The composition of the invention is able toact as a moving structure of reference for multiple detectors (i.e. CT,MR, optical etc.) with a limited lifetime (hours). The advantage ofusing our agent as a multimodal fiducial marker for short-termapplications is that it is much less invasive (and less painful) thanimplanting fiducial markers of any size. In addition, repeatedinjections of the agent could allow for use as a long-term fiducialmarker.

Through size and composition variations (i.e. mixture of known ratios ofone or more carrier of different sizes), differential in vivocirculation, accumulation and clearance kinetics can be achieved inorder to tailor the agent for different imaging applications at the sametime and/or at different times. In this respect, the pharmacokinetics ofa particular composition may be adjusted so as to targetorgans/tissues/cells or tumors that require contrast enhancement. Ifnecessary several different contrast enhancement compositions eachhaving different pharmacokinetic properties can be used to optimizecontrast enhancement of one or more desired regions of interest in amodality specific manner.

The composition of the invention is preferably administered to a subjectusing a pharmaceutical acceptable diluent compatible with thepreservation of the physico-chemical properties of the composition suchas saline solutions. The mode of administration may compriseintravenous, peritoneal, sub-cutaneous, intra muscular or other modes aswould be known to the skilled in the art.

The composition of the invention may be provided in kits comprising thecarrier formulation and signal modifying agents such as to provide amulti-modal image signal modifier composition. The kits may alsocomprise a pharmaceutically acceptable diluent and therapeutic agents.

EXAMPLE 1

Radionuclide imaging in accordance with the method and compositiondescribed above may involve incorporation of derivatized lipids that canchelate the radiometals ^(99m)Tc and ¹¹¹In for SPECT imaging and ⁶⁴Cufor PET. These radionuclides are readily available from a generatorsystem (⁹⁹Mo/^(99m)Tc; Bristol-Myers-Squibb) or can be purchased fromMDS-Nordion Inc. (¹¹¹In and ⁶⁴Cu). PE lipid can be derivatized at theheadgroup with HYNIC for labeling with ^(99m)Tc; DTPA for labeling with¹¹¹In; or with TETA for labeling with ⁶⁴Cu. These bifunctional chelatorsare all commercially available from Macrocyclics Inc. Unilamellarliposomes can be prepared using established methods based onhigh-pressure extrusion and sonication. The labeled liposomes can beformed from the newly synthesized chelator-modified PE and the mixtureof lipids originally employed in the liposome formulation. Followingpreparation, liposomes containing the chelator-modified PE lipid can beincubated with ^(99m)Tc, ¹¹¹In, ⁶⁴Cu or combination thereof in anappropriate labeling buffer for 30 minutes, then the unboundradioactivity can be removed by size-exclusion chromatography.

EXAMPLE 2 Methods and Materials

Materials

The components of liposomes: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine(DPPC, M.W. 734), Cholesterol (CH, M.W. 387) and1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethyleneglycol)2000] (PEG₂₀₀₀DSPE, M.W. 2774) were purchased from NorthernLipids Inc. (Vancouver, British Columbia, Canada). The CT signalmodifying agent, Omnipaque® was obtained from Nycomed Imaging AS, Oslo,Norway. Omnipaque® (300 mg/mL of Iodine) contains iohexol (M.W. 821.14),an iodinated, water-soluble, non-ionic monomeric contrast medium. The MRsignal modifying agent used was ProHance® from Bracco Diagnostics Inc.(Princeton, N.J., USA). ProHance® (78.6 mg/mL of gadolinium) containsgadoteridol (M.W. 558.7), a non-ionic gadolinium complex of10-(2-hydroxy-propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triaceticacid.

Preparation of Liposome Formulations

Lipid mixtures (200 mmol/L) of DPPC, cholesterol and PEG₂₀₀₀DSPE in55:40:5 percent mole ratios were dissolved in ethanol at 70° C. Thelipid-ethanol solution was then hydrated at 70° C. with Omnipaque® andProhance®. The initial ethanol content was 10% vol. The resultingmultilamellar vesicles were then extruded at 70° C. with a 10 mL Lipex™Extruder (Northern Lipids Inc., Vancouver, British Columbia, Canada).Specifically, the samples were first extruded 5 times with two stackedpolycarbonate membranes of 0.2 μm pore size (Nucleopore® Track-EtchMembrane, Whatman Inc., Clifton, N.J., USA) and subsequently 5 timeswith two stacked polycarbonate membranes of 0.08 μm pore size.

Physico-Chemical Characterization Liposome Formulations

Liposome Size and Morphology

The size of liposomes was measured by dynamic light scattering (DLS) at25° C. using a DynaPro DLS (Protein Solutions, Charlottesville, Va.,USA). Liposome morphology was studied by transmission electronmicroscopy (TEM) with a Hitachi 7000 microscope operating at anacceleration voltage of 80 kV. The liposome sample was first diluted indistilled water and then mixed with phosphotungstic acid (PTA) in a 1:1volume ratio. The sample solutions were then deposited onto negativelycharged copper grids that had been pre-coated with carbon.

Evaluation of Loading Efficiency, In Vitro Stability and In VitroRelease Kinetics

Following liposome preparation (the average molecular weight of eachliposome was estimated to be 5×10⁸ g/mol) the unencapsulated agent wasremoved by membrane dialysis. Specifically, 1 mL of the liposome samplewas placed in an 8000 molecular weight cut-off (MWCO) dialysis bagsuspended in 250 mL of HEPES buffer saline (HBS) and left to stir for 8hours. The liposomes were then ruptured using a 10-fold volume excess ofethanol in order to measure the concentration of encapsulated agents.The iodine concentration was determined using a UV assay with detectionat a wavelength of 245 nm (Heλios γ, Spectronic Unicam, MA, USA). Thegadolinium concentration was determined using an assay based oninductively coupled plasma atomic emission spectrometry (ICP-AES Optima3000DV, Perkin Elmer, Mass., USA). The encapsulation efficiency of theagents was calculated using the following equation:

${\%\mspace{14mu}{encapsulation}\mspace{14mu}{efficiency}} = {\frac{{amount}\mspace{14mu}{of}\mspace{14mu}{agent}\mspace{14mu}{enccapsulated}}{{amount}\mspace{14mu}{of}\mspace{14mu}{agent}\mspace{14mu}{added}\mspace{14mu}{during}\mspace{14mu}{preparation}} \cdot 100}$

The in vitro release kinetic profile for both agents was assessed by thedialysis method (Liu J, Xiao Y, Allen C. J Pharm Sci 2004; 93:132-143.).In short, 1 mL of the liposome sample was placed in a dialysis bag (MWCO8000) suspended in 250 mL of HBS and incubated at 4° C. or 37° C. Atspecific time points, 5 mL of the dialysate was removed for measurementof the iodine and gadolinium concentrations and 5 mL of fresh HBS wasadded in order to maintain constant volume. The stability of theliposomes was assessed by measuring the size of liposomes at specifictime points during the incubation period.

In Vitro CT and MR Imaging

In vitro contrast efficacy was determined by imaging the liposomeformulated signal modifying agents at varying concentrations in both CTand MR, using a multimodal imaging phantom. To minimize the amount ofagent leakage from liposomes, in vitro imaging scans were performedimmediately following the removal of free agents by dialysis. CTscanning was performed using a GE LightSpeed Plus 4-detector helicalscanner (General Electric Medical Systems, Milwaukee, Wis., USA) withthe following scan parameters: 2.5 mm slice thickness, 120 kV, 300 mAand 15.2×15.2 cm field of view (FOV). The mean attenuation in Hounsfieldunits was measured using circular regions of interest (ROI). Attenuationvalues were then plotted against signal modifying agent concentrationsusing linear regression analysis.

MR imaging was performed with a 1.5 Tesla GE Signa TwinSpeed MR scannerand a head coil (General Electric Medical Systems, Milwaukee, Wis.,USA). The phantom and the vials were filled to capacity to minimizeair-induced susceptibility artefacts. Scans were produced using a T1weighted spin echo sequence with a repetition time (TR) of 400 ms, anecho time (TE) of 9 ms, a slice thickness of 3 mm, a FOV of 19.9×19.9 cmand an image carrier of 256×192 pixels. The relative signal intensitywas taken over the ROI. Solutions of free signal modifying agents werealso imaged as controls in both modalities.

In Vitro Relaxometry

All in vitro relaxometry measurements were performed at 20° C. on a 1.5Tesla, 20-cm-bore superconducting magnet (Nalorac Cryogenics Corp.,Martinez, Calif.) controlled by an SMIS spectroscopy console (SMIS,Surrey, UK). The T₁ relaxation time data were acquired using aninversion recovery (IR) sequence (45) with 35 inversion recovery time(TI) values logarithmically spaced from 1 to 32000 ms. A 10 second delaywas given between each acquisition and the next inversion pulse. The T₂relaxation time data were acquired using a CPMG sequence (Carr H,Purcell E. Phys Rev 1954; 94:630-638; Meiboom S, Gill S. 1958;29:668-691.) with TE/TR=1/10000 ms. For every measurement 2000 evenechoes were sampled with 8 averages. The effects of any residualtransverse magnetization following the off-resonance irradiation wasremoved by phase-cycling the π/2 pulse (−x/x).

The T₁ relaxation data were analyzed assuming mono-exponential behaviour

$\left( {{S = {M_{0} \cdot \left( {1 - {2 \cdot {\mathbb{e}}^{- \frac{t}{T\; 1}}}} \right)}},} \right.$where S is the signal observed, M₀ is the magnetization at equilibrium,t is time and T₁ is the longitudinal relaxation time). All T₂ decay datawere plotted to a one component T₂ model with a Gaussian fit on alogarithmic time scale. The r₁ and r₂ values were calculated from linearregression analysis of 1/T₁ and 1/T₂ relaxation rates versus gadoliniumconcentration.ResultsPhysico-Chemical Characterization of Liposome Formulation

The prepared liposome formulation resulted in vesicles having aspherical morphology (FIG. 2) and a mean diameter of 74.4±3.3 nm. Table1 summarizes the agent loading properties of the liposome formulation.The average loading efficiency (n=8) achieved for iohexol was 19.6±2.8%(26.5±3.8 mg/mL iodine loaded, approximately 1.3×10⁶ iodine moleculesper liposome), which represents an agent to lipid ratio of approximately0.2:1 (wt:wt). The average loading efficiency (n=8) attained forgadoteridol was 18.6±4.4% (6.6±1.5 mg/mL gadolinium loaded,approximately 1.3×10⁵ gadolinium molecules encapsulated in oneliposome), which represents an agent to lipid ratio of approximately0.05:1 (wt:wt).

TABLE 1 Iodine Gadolinium Iodine Iodine loading Gadolinium Gadoliniumloading Diameter added loaded efficiency added loaded efficiency (nm)(mg/mL) (mg/mL) (%) (mg/mL) (mg/mL) (%) 74.4 ± 3.3 135 26.5 ± 3.8 19.6 ±2.8 35.5 6.6 ± 1.5 18.6 ± 4.4

FIG. 3 includes the in vitro release profile for both agents under sinkconditions in physiological buffer at 4° C. (FIG. 3 a) and 37° C. (FIG.3 b). As shown, following the 15-day incubation period at 4° C.,8.7±1.5% and 6.6±4.5% of the encapsulated iodine and gadolinium werereleased, respectively, and at 37° C., 9.1±2.5% and 7.5±1.4% of theencapsulated iodine and gadolinium were released, respectively. Theliposomes were also sized periodically during the incubation period inorder to assess their stability under sink conditions in HBS at 37° C.As seen in FIG. 4 the liposome size remains constant throughout theincubation period.

In Vitro Imaging

Visual contrast enhancement was observed in CT and MR when theliposome-based signal modifying agent was imaged in vitro at varyingconcentrations (FIGS. 5 a and 5 b).

FIG. 6 a illustrates the measured CT attenuation of the liposomeencapsulated signal modifying agents, the unencapsulated iohexol, theunencapsulated gadoteridol and the mixture of unencapsulated iohexol andgadoteridol. Attenuation values varied linearly with concentration forall signal modifying agent solutions. Linear regression analysisrevealed an attenuation of 11.1±0.5 HU/(mg of gadolinium) in 1 mL of HBSfor the unencapsulated gadoteridol (r=0.99), 29.0±0.4 HU/(mg of iodine)in 1 mL of HBS for the unencapsulated iohexol (r=0.99), 38.8±0.5 HU/(mgof iodine and 0.2 mg of gadolinium) in 1 mL of HBS for the mixture ofunencapsulated iohexol and gadoteridol (r=0.99), and 36.3±0.5 HU/(mg ofiodine and 0.2 mg of gadolinium) in 1 mL of HBS for the liposomeformulation (r=0.99). The slightly lower attenuation values observed forthe liposome encapsulated iohexol and gadoteridol compared to freeiohexol and gadoteridol are due to the presence of lipids, which, withrespect to water, have lower CT attenuation values (between −60 and −100HU).

FIG. 6 b illustrates the MR relative signal profile as a function ofgadolinium concentration. It is known that the linearity betweengadolinium concentration and relative signal intensity in MR is lostwhen critical values of gadolinium concentration are reached (Takeda M,Katayama Y, Tsutsui T, et al. Tohoku J Exp Med 1993; 171:119-128;Tweedle M F, Wedeking P, Telser J, et al. Magn Reson Med 1991;22:191-194; discussion 195-196; Morkenborg J, Pedersen M, Jensen F T, etal. Magn Reson Imaging 2003; 21:637-643). Furthermore, negativeenhancement occurs in MR when the gadolinium concentration reaches highenough levels to cause significant T₂ shortening, which in turn causessignal loss (Choyke P L, Frank J A, Girton M E, et al. Radiology 1989;170:713-720; Carvlin M J, Arger P H, Kundel H L, et al. Radiology 1989;170:705-711; May D A, Pennington D J. Radiology 2000; 216:232-236; DavisP L, Parker D L, Nelson J A, et al. Invest Radiol 1988; 23:381-388). Thethree plots in FIG. 6 b for liposome encapsulated gadoteridol andiohexol, free gadoteridol and iohexol and free gadoteridol all exhibitnon-linear characteristics. The free iohexol plot confirms that iodinein the concentration range of 0 to 17 mmol/L shows signal intensitylevels comparable to those achieved by water. The average differentialsignal intensity (SI) in MR for free iohexol samples was 1.8±7.1 SIrelative to water. The unencapsulated gadoteridol samples reached peakdifferential signal intensities (>600 SI with respect to water) in thegadolinium concentration range of 1 to 9 mmol/L. This is in accordancewith previous findings (Morkenborg J, Pedersen M, Jensen F T, et al.Magn Reson Imaging 2003; 21:637-643; Choyke P L, Frank J A, Girton M E,et al. Radiology 1989; 170:713-720; Carvlin M J, Arger P H, Kundel H L,et al. Radiology 1989; 170:705-711; May D A, Pennington D J. Radiology2000; 216:232-236.). A decrease in signal intensity (up to 20%) wasobserved when free gadoteridol was mixed with iohexol. This finding isconsistent with previous reports on the capability of iodinated signalmodifying agents to diminish the signal enhancing effects of gadolinium(Montgomery D D, Morrison W B, Schweitzer M E, et al. J Magn ResonImaging 2002; 15:334-343; Kopka L, Funke M, Fischer U, et al. AJR Am JRoentgenol 1994; 163:621-; Kopka L, Funke M, Fischer U, et al. Rofo1994; 160:349-352). Encapsulation of gadoteridol and iohexol in liposomewas found to cause a right shift in the differential signal intensityprofile (peak signal intensities in MR achieved with gadoliniumconcentration ranging from 5 to 18 mmol/L). Encapsulation of gadoteridolin the interior of liposomes diminishes MR signal at lower gadoliniumconcentrations (<5 mmol/L) due to limited bulk water access whichdecreases 1/T₁ values (Fossheim S L, Fahlvik A K, Klaveness J, et al.Magn Reson Imaging 1999; 17:83-89.). At higher gadolinium concentrations(>5 mmol/L), however, encapsulation of gadoteridol significantly dampensthe T₂ relaxation effect allowing high signal levels to be maintainedover a much broader gadolinium concentration range in MR.

In Vitro Relaxometry

For the relaxometry measurements, T₁ (FIG. 7 a) and T₂ (FIG. 7 b) rateswere observed to be linear and concentration dependent for both theliposome encapsulated and the unencapsulated signal modifying agents.The r₁ and r₂ values of unencapsulated gadoteridol were 5.1 and 6.2 s⁻¹mmol⁻¹L, respectively. The r₁ and r₂ values for gadoteridol in thepresence of iohexol were 6.4 and 7.8 s⁻¹ mmol⁻¹L, respectively, and ther₁ and r₂ values for the liposome encapsulated agents were 1.2 and 1.5s⁻¹ mmol⁻¹L. The r₁ and r₂ values for iohexol were found to be 0.0 s⁻¹mmol⁻¹L. Therefore, the encapsulation of the paramagnetic agentgadoteridol in liposomes significantly reduces both the 1/T₁ and 1/T₂relaxivity values, in accordance with FIG. 6 b, as well as previouslypublished data (Fossheim S L, Fahlvik A K, Klaveness J, et al. MagnReson Imaging 1999; 17:83-89.).

In Vivo Imaging

FIG. 8 provide an example of how the liposome-based multimodal signalmodifying agent can provide structure correspondence for registrationand fusion of images acquired from different imaging modalities.

Optical Imaging

Optical contrast enhancement imaging is demonstrated in FIG. 9 wherein aconfocal microscopy image of carrier comprising gadoteridol, iohexol anda fluorophore is shown. Such a carrier would therefore be suitable forMRI, CT and optical imaging or combination thereof.

Examples of multi-modal agents for use in fluorescence optical imagingmay include preparation of two types of lipids: (1)phosphatidylethanolamine (PE) conjugated with the fluorescent probe(example: PE-Alexa Fluor 680) and (2) PE conjugated with biotin (i.e.PE-biotin). These lipids can serve as building blocks or components ofthe lipid bilayer and thus enable the multi-modal agent to support nearIR fluorescence optical imaging. Near IR optical fluorescence imaginghas the advantage of operating at a wavelength range at which mosttissues exhibit low inherent scattering and minimal absorption and it isknown to have a higher penetration depth, making it more useful for invivo imaging applications. Following preparation, liposomes containingthe PE-biotin lipid can be incubated with a streptavidin or avidinconjugated fluorescent probe with removal of the excess probe using gelfiltration chromatography. It will be appreciated that other approachesto incorporate a fluorophore in the image signal modifier of theinvention can be used as would be known to the skilled in the art.

In the case of CT, agents containing elements with high atomic number,such as iodine, are able to increase the differential x-ray attenuationbetween different soft tissues and organs. Whereas, MR signal modifyingagents made up of paramagnetic metals, such as gadolinium, are able todeliver signals by increasing surrounding tissue relaxivity.Furthermore, the differences in intrinsic sensitivity and resolutionbetween the two imaging modalities create a requirement forsubstantially different concentrations of each reporter moiety in orderto achieve adequate signal intensity. For example, in a clinicalcontext, MR is sensitive to gadolinium concentrations between 1-10μg/mL, while CT requires at least 1 mg/mL of iodine for detection. Amultimodal signal modifying composition with efficacy in CT and MRshould preferably accommodate this 100-fold differential in sensitivityand minimize any agent-related signal interferences across differentimaging modalities.

In a study liposomes were selected as a system for delivery of CT and MRsignal modifying agents at appropriate concentrations. Encapsulation ofiohexol in liposomes does not affect the CT attenuation capability ofthis agent; therefore, as long as a sufficient quantity of iodine isloaded into the interior of the liposomes adequate signal enhancement isexpected; although gadolinium relaxation is greatly dependent on theamount of water that the gadolinium atoms can access when encapsulated,the permeability of the liposome membrane can be easily adjusted byvarying the lipid composition and cholesterol content (Raffy S, TeissieJ. Biophys J 1999; 76:2072-2080; Lasic D D. Trends Biotechnol 1998;16:307-321; Drummond D C, Meyer O, Hong K, et al. Pharmacol Rev 1999;51:691-74). In addition, liposomes constitute a highly versatiledelivery system. Their size can be easily altered and monodisperse sizedistributions may be achieved by preparation of the formulation usingthe high-pressure extrusion method. Also, the surface of liposomes maybe modified in order to create vehicles suitable for specificapplications. For example, the addition of PEG to the liposome surfacehas been shown to increase the in vivo circulation lifetime of thesevehicles (Allen C, Dos Santos N, Gallagher R, et al. Biosci Rep 2002;22:225-250; Allen T M, Hansen C. Biochim Biophys Acta 1991;1068:133-141). It has also been found that PEGylated liposomes canachieve up to two times higher r₁ relaxivity values compared toconventional liposomes. The increase in the r₁ relaxivity values for thePEGylated liposomes has been attributed to the presence ofPEG-associated water protons in the vicinity of the liposome membrane(Trubetskoy V S, Cannillo J A, Milshtein A, et al. Magn Reson Imaging1995; 13:31-37). Specific moieties may also be conjugated to theliposome surface in order to actively target specific tissues or cells.In this way, with the appropriate surface modifications, liposome-basedsignal modifying agents may become suitable candidates for use infunctional, molecular and optical imaging applications.

Systems for delivery of signal modifying agents for use in blood-pooland lymphatic imaging applications should have minimal agent release invivo. A stable formulation with slow release profiles for both agentsallows for prolonged imaging studies and repeated scans in CT and MR. Itis known that extracellular agents with small molecular weights such asiohexol and gadoteridol have a much faster clearance profile in bloodcompared to colloidal carriers such as liposomes (Saeed M, Wendland M F,Higgins C B. J Magn Reson Imaging 2000; 12:890-898.). Therefore, as theencapsulated agents are released from the liposomes, the signalenhancement will diminish in both CT and MR at a rate that isproportional to that of agent release and clearance. The slow agentrelease profiles (<9% of each agent released over 15 days, FIG. 3) andstability (liposome size remained unchanged over 15 days, FIG. 4)achieved in vitro for the current liposome formulation provide adequateretention to achieve image enhancement.

The imaging efficacy in CT and MR of the liposome-based signal modifyingagent was assessed in vitro with a purpose-built phantom (FIGS. 5 a, 5b, 6 a and 6 b). The 1/T₁ and 1/T₂ relaxivity characteristics of theagent were also investigated (FIGS. 7 a and 7 b). From the resultsobtained, it can be concluded that in order to achieve 100 HU ofattenuation in CT, ˜2.7 mg/mL of the liposome encapsulated iodine isneeded, and in order to achieve significant MR enhancement (>600 SIdifferential signal intensity with respect to water) a minimum of 5mmol/L (˜0.8 mg/mL) of the encapsulated gadolinium is necessary. It willbe appreciated that other signal intensity enhancement can be obtainedusing different concentration of signal modifying agents. The loadingcharacteristics of the current system under investigation (Table 1)allow for significant contrast enhancement in both imaging modalities tobe maintained for up to a 10-fold volume dilution following injection.

EXAMPLE 3 Materials

The following lipids: 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC,M.W. 734), Cholesterol (CH, M.W. 387) and1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethyleneglycol)2000] (PEG₂₀₀₀DSPE, M.W. 2774) were purchased from NorthernLipids Inc. (Vancouver, British Columbia, Canada). Omnipaque® wasobtained from Nycomed Imaging AS, Oslo, Norway. Omnipaque® (300 mg/mL ofiodine) contains iohexol (M.W. 821.14), an iodinated, water-soluble,non-ionic monomeric contrast medium. ProHance® from Bracco DiagnosticsInc. (Princeton, N.J., USA). ProHance® (78.6 mg/mL of gadolinium)contains gadoteridol (M.W. 558.7), a non-ionic gadolinium complex of10-(2-hydroxy-propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triaceticacid.

Liposome Preparation

200 mmol/L of the DPPC, cholesterol and PEG₂₀₀₀DSPE (55:40:5 mole ratio)mixture was dissolved in ethanol at 70° C. and then hydrated withOmnipaque® and Prohance®. The total ethanol content was 10%_(vol). Theresulting multilamellar vesicles were sonicated for 1 minute for each mLof liposome solution to yield unilamellar vesicles.

Liposome Characterization

Size and Morphology

The size of liposomes was measured by dynamic light scattering (DLS) at25° C. using a DynaPro DLS (Protein Solutions, Charlottesville, Va.,USA). Transmission electron microscopy (TEM, Hitachi 7000 microscope)was used to assess the liposome morphology. TEM was operated at anacceleration voltage of 75 kV. The liposome sample was first diluted indistilled water and then mixed with phosphotungstic acid (PTA) in a 1:1volume ratio. The sample solutions were then deposited onto negativelycharged and carbon pre-coated copper grids.

In Vivo CT and MR Imaging

The following study was performed under a protocol approved by theUniversity Health Network Animal Care and Use Committee. The female NewZealand white rabbit weighing 2.1 kg was anesthetized with anintramuscular injection of 40 mg/kg of ketamine and 5 mg/mL of xylazine,followed by 2% isoflurane vapor given by inhalation. The signalmodifying agent was injected with an automated injector connected to themarginal ear vein catheter at a rate of 1 mL/second. For the MR scan, 10mL of the signal modifying agent solution (75 mg/kg of iodine and 83mg/kg of gadolinium encapsulated in lipsomes) was injected and flushedwith 20 mL of saline solution. MR imaging was performed with a 1.5 TeslaGE Signa TwinSpeed MR scanner (General Electric Medical Systems,Milwaukee, Wis., USA). Scans were produced using a 3D FSGR sequence witha repetition time (TR) of 7.2 ms, an echo time (TE) of 1.6 ms, a slicethickness of 3.4 mm with an overlap of 1.7 mm, a field of view (FOV) of27.8×27.8 cm and a matrix of 256×224. The signal intensity (SI) wasmeasured in selected tissues using circular regions of interest (ROI).

The CT scan was performed 4 days after the MR scan to allow for completeclearance of the signal modifying agent. For the CT scan 20 mL of thesignal modifying agent solution (150 mg/kg of iodine and 166 mg/kg ofgadolinium encapsulated in liposomes) was injected and flushed with 20mL of saline solution. CT imaging was performed using a GE LightSpeedPlus 4-slice helical scanner (General Electric Medical Systems,Milwaukee, Wis., USA) with the following scan parameters: 2.5 mm slicethickness, 120 kV, 200 mA and 49.9×49.9 cm FOV. The mean attenuation inHounsfield units (HU) in selected regions of interest was measured usingROI.

Both MR and CT scanning sequences were repeated at known time intervalsfollowing signal modifying agent injection (3, 5, 7, 10, 15, 20, 25, 30,45, 60, 75, 90, 105, 120, 135, 150, 165, 180, and 200 minutes).

Results

In Vivo Imaging

CT and MR image analysis were performed using circular ROI in the aorta,the liver parenchyma, the kidney medulla and cortex before and afterinjection of signal modifying agent to obtain relative enhancementvalues. FIG. 10 a shows the CT relative attenuation curve vs. time afterinjection for the tissues of interest. The average differentialattenuation was 81.4±13.05 ΔHU in the blood (aorta), 38.0±5.1 ΔHU in theliver parenchyma, 14.8±10.3 ΔHU in the kidney medulla and 9.1±1.7 ΔHU inthe kidney cortex 200 minutes following injection. FIG. 10 b illustratesthe relative signal intensity changes vs. time in MR. At the studyendpoint (200 minutes following injection), an enhancement of731.9±144.2 ΔSI was measured in the aorta, 178.6±41.4 ΔSI in the liverparenchyma, 833.61±33.84 ΔSI in the kidney medulla and 461.7±78.1 ΔSI inthe kidney cortex.

Signal enhancement in the aorta, the liver parenchyma and the kidneycortex reached peak values approximately 10 minutes following theadministration of the signal modifying agent. A gradual decrease insignal values occurred over the remaining 190 minutes (FIG. 11 a) inboth imaging modalities. In the kidney medulla, however, although boththe CT and MR differential signal curves peaked 30 minutes followingsignal modifying agent injection, the CT signal eventually decreased tolevels similar to those found in the kidney cortex (consistent with apreviously published liposome-based CT agent), while the signal in MRgradually leveled to values similar to those achieved in blood (FIG. 11b).

The impressive in vitro stability and release behavior of thisformulation was demonstrated to translate into prolonged in vivoresidence times and maintenance of significant signal enhancement bothlocally (in the liver and kidney) and systemically (in the blood stream)in CT and MR (FIGS. 10 and 11). The substantial signal increase achievedand maintained in the aorta (81.4±13.05 ΔHU in CT and 731.9±144.2 signalintensity ΔSI in MR 200 minutes after injection) suggested that thisliposome-based signal modifying agent holds great potential for bloodpool imaging, particularly for cardiovascular applications. Theenhancement obtained in the liver and the kidney offered insight intothe route by which this formulation is cleared in vivo. Based onpreviously published data, the primary route of clearance fordrug-carrying stealth PC liposomes is the liver. This is consistent withthe high signals achieved and maintained in the liver parenchyma in bothimaging modalities over the course of this study. Without wishing to bebound by any theory, the increase in signal (measured in both CT and MR)in the kidney medulla during the first half hour followingadministration may be attributed to the initial burst release of theencapsulated agents from the liposomes (refer to FIG. 10). Followingrelease of the encapsulated agents from the liposomes, they are clearedvia the renal route due to their low molecular weights. It is worthnoting that in CT, 200 minutes post injection, the levels of signal inthe kidney medulla and cortex returned to values close to those obtainedprior to signal modifying agent injection. While in MR, although thesignal in both the medulla and the cortex decreased gradually over time,at the 200 minute time point, the signal measured in the medulla wasstill significantly higher than that measured in the cortex. A possibleexplanation for this is the difference in the clearance rates foriohexol and gadoteridol from the kidneys. The non-linearity in therelationship between MR signal and gadolinium concentration may alsohave contributed to the difference between the signal levels measured inthe kidney medulla for the two imaging modalities.

The parallel and prolonged contrast enhancement achieved in CT and MRmakes this signal modifying agent ideal for multimodality imageregistration. For example, cases of mis-registration due to unpredictedsignal variations in different imaging modalities in the regions ofinterest would be greatly reduced with its use. Its long in vivoresidence time will allow for multiple scans to be obtained following asingle injection. This in turn will enable the direct correlation of thesignals obtained in distinct imaging modalities and allow for correctcorrespondence between different regions in the image. This multimodalsignal modifying agent may also assist in the development of novel imageregistration techniques, such as biomechanical based registration, whichcan take advantage of the clear definition of organ boundaries andsubstructures enhanced in each modality. In addition to improving theperformance of image registration techniques, this signal modifyingagent may also enhance the ability to identify naturally occurringfiducial points (i.e. vessel bifurcations) used to verify the accuracyof registration techniques.

EXAMPLE 4

In an additional study, a longitudinal imaging-based assessment of thein vivo stability (FIG. 12) of the signal modifying agent modifiedliposome was conducted in a rabbit model (2 kg New Zealand White rabbit,10 mL of the signal modifying agent loaded liposome solution containing200 mg/kg of iodine and 16 mg/kg of gadolinium). Visual contrastenhancement and measurable signal increases produced by the presence ofsignal modifying agent carrying liposomes was induced in various organsystems (i.e. heart and blood vessels, liver, spleen, kidney andintestines) in both CT and MR over a 7-day period. Following theextraction of each agent from rabbit plasma, it was determined that17.7% of the injected iohexol (95.9 μg/mL of iodine) and 17.3% of theinjected gadoteridol (7.9 μg/mL of gadolinium) still circulated in thebloodstream 7 days post-injection. The plasma circulation half-life ofthe present liposome formulation in rabbits was found to beapproximately 45 hours (and approximately 25 hours in Balb-C mice, FIG.13). A biodistribution study was also performed in Balb-C miceidentifying the tissue distribution of liposomes using gadolinium as asurrogate marker (FIG. 14).

Correlations were established between the iodine and gadoliniumconcentrations found in the rabbit plasma and the signal enhancementobtained in the rabbit aorta in CT and MR, relatively, using circularregions of interest over 6 time points (10 minutes, 24, 48, 72, 120 and168 hours post-injection). Fairly linear relationships (R2=0.9) werefound between the iodine concentration and relative HU increase in CT,and between the gadolinium concentration and relative signal intensityincrease in MR (FIG. 15).

EXAMPLE 5

The signal modifying agents used in CT and MR can be entrapped duringliposome preparation; while for optical and radionuclide imaging thespecific building blocks (i.e. derivatized lipids) can be incorporatedinto the lipid bilayer. The commonly employed non-exchangeable,non-metabolizable lipid marker ³[H]-cholesterol hexadecyl ether (CHE)can also be incorporated into the liposomes. The signal modifyingcomposition can be administered i.v. via the dorsal tail vein to normalhealthy Balb/c mice and animals can be imaged post-administration atspecific time points (i.e. 30 mins., 1, 2, 4, 6, 8, 12, 24, 36, 48, 72hrs.) Also, following each imaging time point, the mice can besacrificed by cervical dislocation and samples of blood, liver, spleen,kidneys and other tissues excised, weighed and analyzed in order todetermine the concentrations of lipid (liquid scintillation counting for³H-CHE), CT agent (HPLC analysis with UV detection for iohexol), MRagent (ICP-AES for gadoteridol), fluorescence optical agent (HPLC withfluorescence detection) and/or radionuclide (γ-counter). The ratio ofagent or radionuclide to lipid can be calculated for each time point inorder to evaluate the retention of agent in the carrier. Also, theresults from imaging can be compared to the actual concentration ofcontrast agent or radionuclide in the blood and tissues in order todetermine the sensitivity and linearity of the imaging signal.

EXAMPLE 6

Active targeting can be evaluated in a well-established mouse tumourxenograft model of human breast cancer that has been used routinely forevaluation of novel radiopharmaceuticals for breast cancer imaging andtargeted radiotherapy. The model consists of athymic mice implantedsubcutaneously with MDA-MB-468 human breast cancer cells thatoverexpress epidermal growth factor receptors (EGFR) (1×10⁶ EGFR/cell).The EGFR is arguably one of the most well-validated targets on solidtumors ever studied. Interest in targeting the receptor has led to atleast two FDA-approved targeted agents for treatment of EGFR-positivemalignancies: Iressa™ (Astra-Zeneca), a small molecule tyrosine kinaseinhibitor, and Erbitux™ (Imclone), a monoclonal antibody (mAb) directedat the extracellular ligand-binding domain.

Preparation of Actively Targeted Multi-Modal Agents

Active targeting can be can be enabled by using derivatized lipids. Forexample, N-hydroxy succinimydyl ester terminated PEG conjugated PE(PE-PEG-NHS) and biotin terminated PEG conjugated PE (PE-PEG-biotin).The PE-N-PEG-NHS may be used to couple peptides or proteins with a freeamino terminus or ε-NH₂ group to the liposomes (e.g. EGF); while, thePE-N-PEG-biotin may be used to attach the wide range of available biotinfunctionalized ligands to the liposomes using streptavidin as thecoupling agent. EGFR targeted liposomes can be formed from PE-N-PEG-NHSand the mixture of lipids described above (i.e. DPPC, cholesterol andPEG₂₀₀₀DSPE). For imaging in CT and MR the agents can be entrappedduring liposome preparation; while, for optical and radionuclide imagingthe specific building blocks (i.e. derivatized lipids) can beincorporated into the lipid bilayer. Following preparation, theliposomes containing the PE-N-PEG-NHS lipid can be mixed with EGF in PBSfor 24 hours and the reaction mixture can then be dialyzed in order toremove the uncoupled EGF. The EGF-conjugation efficiency can be measuredusing the Micro BCA Protein Assay. The size and stability of theEGF-conjugated-liposomes can be evaluated using DLS. The ability of theEGF-coupled liposomes to interact with their receptors on MDA-MB-468cells can be evaluated by flow cytometry or by direct or competitionradioligand binding assays.

Evaluation of EGFR-Targeted Multi-Modal Agents in Mouse Model of BreastCancer

The liposomes can be administered i.v. via the dorsal tail vein toathymic mice bearing MDA-MB-468 s.c. human breast cancer xenografts(0.25-0.5 cm diameter). The tumour and normal tissue uptake as well asimaging properties of the signal modifying composition can be evaluated.Region-of-interest (ROI) analysis can be performed on the images toevaluate accumulation in the tumour and identifiable organs.Specifically, the kinetics of tumour uptake as well as temporal andspatial distribution of the targeted (and non-targeted liposomes forcomparison) can be determined. In addition, following select imagingtime points, groups of mice can be sacrificed by cervical dislocationand samples of blood, tumour, liver, spleen, and other tissues excised,weighed and analyzed in order to determine the concentration of lipidand contrast agent (iohexol, gadoteridol or radionuclide). Thespecificity of targeting can be evaluated by comparison with imaging andbiodistribution studies in mice pre-administered a 500-fold molarexpress of unconjugated EGF to saturate EGFR on the tumours, Acomparison of the tumour and normal tissue uptake of targeted andnon-targeted multi-modal contrast agent can also be made, since weexpect that some tumour accumulation of the non-targeted agent may occurthrough the enhanced vascular permeability observed in solid tumours.These multi-modality imaging studies which simultaneously collect two ormore signals can reveal important and potentially large differences inthe sensitivity of detection of MR, CT and nuclear or fluorescentoptical imaging with respect to their capability to detect phentotypicproperties of tumours.

The references cited in the present description are all included hereinby reference.

While the invention has been described in connection with specificembodiments thereof, it will be understood that it is capable of furthermodifications and this application is intended to cover any variations,uses, or adaptations of the invention following, in general, theprinciples of the invention and including such departures from thepresent disclosures as come within known or customary practice withinthe art to which the invention pertains and as may be applied to theessential features herein before set forth, and as follows in the scopeof the appended claims.

The invention claimed is:
 1. A composition for imaging of a biologicaltissue, said composition comprising: a) two or more separate andunlinked signal modifying agents, each of said agents being specific forat least one imaging modality and each of said agents being specific fora different imaging modality; and b) a colloidal carrier comprising saidtwo or more signal modifying agents wherein said carrier retains asufficient amount of said agents for a time sufficient to acquire invivo imaging data from each of the two or more signal modifying agentsusing said composition, and said colloidal carrier is a liposomecomprising at least one lipid, cholesterol, and at least one pegylatedlipid; and wherein said composition is specific for two or more imagingmodalities selected from magnetic resonance imaging (MRI), X-ray,positron emission tomography (PET), computed tomography (CT),autoradiography, single-photon emission computed tomography (SPECT),fluoroscopy, optical imaging, fluorescence imaging, bioluminescenceimaging and combinations thereof and each of the signal modifying agentsis present at a different concentration that is sufficient to acquire invivo imaging data from an imaging modality for which said signalmodifying agent is specific, wherein said composition comprises i) asignal modifying agent specific for MRI comprising gadoteridol and asignal modifying agent specific for CT comprising iohexol, ii) a signalmodifying agent specific for optical imaging comprising a fluorophoreand a signal modifying agent specific for CT comprising iohexol or iii)a signal modifying agent specific for optical imaging comprising afluorophore and a signal modifying agent specific for MRI comprisinggadoteridol.
 2. The composition as claimed in claim 1 wherein saidcarrier has a retention efficiency of about 10 to 100% for a timesufficient to acquire imaging data.
 3. The composition as claimed inclaim 1 wherein said carrier has a retention efficiency of about 80 to100% for a time sufficient to acquire imaging data.
 4. The compositionas claimed in claim 1 wherein said composition provides signalmodification for image data acquisition in said biological tissue for apredetermined amount of time.
 5. The composition as claimed in claim 4wherein said predetermined amount of time is between about 1 minute andabout 14 days.
 6. The composition as claimed in claim 4 wherein saidpredetermined amount of time is between about 5 minutes and about 7days.
 7. The composition as claimed in claim 1 wherein said two or moreseparate and unlinked signal modifying agents are specific for imagingmodalities selected from MRI, CT, optical imaging and combinationsthereof.
 8. The composition as claimed in claim 1 wherein said two ormore separate and unlinked signal modifying agents are specific forimaging modalities selected from MRI, CT, PET, SPECT, optical imagingand combinations thereof.
 9. The composition as claimed in claim 8wherein said signal modifying agents specific for MRI comprisegadolinium, said signal modifying agents specific for CT compriseiodine, said signal modifying agents specific for PET and SPECT comprisea positron emitting radioisotope or a gamma ray emitting radioisotopeand said signal modifying agents specific for optical imaging comprise afluorophore.
 10. The composition as claimed in claim 1 wherein saidlipid is phosphatidylcholine (PC) and said PEGylated lipid ispolyethylene glycol-phophatidylethanolamine (PEG-PE).
 11. Thecomposition as claimed in claim 10 wherein said PC:CHOL:PEG-PE are in amolar ratio of about 55:40:5.
 12. The composition as claimed in claim 11wherein said PC is Dipalmitoyl-PC(DPPC) and said PEG-PE isPEG2000-Distearoyl-PE(PEG2000-DSPE).
 13. The composition as claimed inclaim 1 wherein said liposomes have a diameter of between about 30 nmand about 1000 nm.
 14. The composition as claimed in claim 13 whereinsaid liposomes have a diameter of between about 30 nm and about 500 nm.15. The composition as claimed in claim 14 wherein said liposomes have adiameter of between about 50 nm and 150 nm.
 16. The composition asclaimed in claim 1 wherein said carrier is targeted to a specific targetwithin a mammal.
 17. The composition as claimed in claim 16 wherein saidtargeting is achieved through control of said carrier's physico-chemicalproperties.
 18. The composition as claimed in claim 16 wherein saidcarrier comprises one or more recognition molecules to achievetargeting.
 19. The composition as claimed in claim 18 wherein saidtarget is a cell population.
 20. The composition as claimed in claim 18wherein said one or more recognition molecules are selected fromantibodies, receptors/ligands, carbohydrates, proteins and peptidefragments.
 21. The composition as claimed in claim 1 further comprisinga therapeutic agent.
 22. The composition as claimed in claim 21 whereinsaid therapeutic agent is selected from anticancer, antimicrobial,antifungal and antiviral agents.
 23. A method for registering imagesobtained from two or more imaging modalities said method comprising: a)administering to a mammal a composition as claimed in claim 1, eachagent being specific for at least one of said two or more imagingmodalities; b) obtaining an image of one or more regions of interest insaid mammal using each of said two or more imaging modalities; and c)comparing the images obtained in b) to derive complementary informationfrom said one or more regions of interest.
 24. The method as claimed inclaim 23 wherein said complementary information is selected fromanatomical information, molecular information, functional information,physiological information and combinations thereof.
 25. The compositionof claim 1, wherein each of signal modifying agents is present at adifferent concentration that is sufficient to acquire in vivo imagingdata from an imaging modality for which said signal modifying agent isspecific in a single administration.
 26. The composition of claim 1,wherein the liposome releases <9% of each of said signal modifyingagents over 15 days when dialyzed under sink conditions against HBS at4° C. or 37° C.
 27. The composition of claim 1, wherein said two or moreseparate and unlinked signal modifying agents that are each specific forat least one imaging modality independently have differing loadingefficiencies for imaging modalities.
 28. The composition of claim 1,wherein said two or more separate and unlinked signal modifying agentshave independent and different release profiles.
 29. A method forimaging one or more regions of interest in a mammal said methodcomprising: a) administering to said mammal the composition as claimedin claim 1; b) waiting for a time sufficient for said composition toreach said region of interest; and c) obtaining two or more images ofsaid one or more regions of interest.
 30. The method as claimed in claim29 wherein said step of waiting further comprises waiting for a timesufficient for said composition to substantially clear from apredetermined region.
 31. The method as claimed in claim 29 wherein saidregions of interest comprises an abnormality and wherein saidabnormality is detected in said images.
 32. The method as claimed inclaim 31 wherein the abnormality is a tumor.
 33. The method as claimedin claim 29 further comprising the step of estimating a pharmacokineticprofile of said composition.
 34. The method as claimed in claim 33further comprising the step of designing an administration regimen basedon said pharmacokinetic profile.
 35. The method as claimed in claim 34wherein said administration regimen is applied to a patient in needthereof.
 36. The method as claimed in claim 35 wherein progress of saidadministration regimen is followed over time by obtaining one or moreimages after said regimen is started.
 37. The method as claimed in claim35 wherein said therapeutic regimen is a regimen for treating cancer.38. The method as claimed in claim 37 wherein said regimen is selectedfrom surgery, radiotherapy, chemotherapy, cell therapy, gene therapy andhyperthermia.
 39. The method as claimed in claim 34 wherein thecomposition further comprises a therapeutic agent and saidadministration regimen is a therapeutic regimen.
 40. A composition forimaging of a biological tissue, said composition comprising: a) two ormore separate and unlinked signal modifying agents, each of said agentsbeing specific for at least one imaging modality and each of said agentsbeing specific for a different imaging modality; and b) a colloidalcarrier comprising said two or more signal modifying agents wherein saidcarrier retains a sufficient amount of said agents for a time sufficientto acquire in vivo imaging data from each of the two or more signalmodifying agents using said composition, and said colloidal carrier is aliposome comprising at least one lipid, cholesterol, and at least onepegylated lipid; and wherein said composition is specific for two ormore imaging modalities selected from magnetic resonance imaging (MRI),X-ray, positron emission tomography (PET), computed tomography (CT),autoradiography, single-photon emission computed tomography (SPECT),fluoroscopy, optical imaging, fluorescence imaging, bioluminescenceimaging and combinations thereof and each of the signal modifying agentsis present at a different concentration that is sufficient to acquire invivo imaging data from an imaging modality for which said signalmodifying agent is specific, wherein one signal modifying agent isspecific for MRI and comprises gadolinium at a concentration >5 mmol/Land wherein another signal modifying agent is specific for CT andcomprises iodine at a concentration of at least 1 mg/ml.
 41. A methodfor imaging one or more regions of interest in a mammal said methodcomprising the steps of: a) administering to said mammal the compositionof claim 40; b) waiting for a time sufficient for said composition toreach said region of interest; and c) obtaining two or more images ofsaid one or more regions of interest.